FDA approves Inovio's treatment for rare throat disease; shares surge

 The US Food and ‌Drug Administration has ‌approved Inovio Pharmaceuticals' treatment ​for a rare respiratory condition, the regulator said on ‌Friday, marking ⁠the company's first approved product.

Shares ⁠of Inovio were up 215% in ​extending trading.

Inovio's ​therapy ​INO-3107, branded ‌as Voceryq, gives patients with recurrent respiratory papillomatosis a new treatment option for ‌the condition, ​which causes ​growths ​in the ‌airways and often requires ​repeated ​surgeries.

https://finance.yahoo.com/healthcare/articles/us-fda-approves-inovios-treatment-204453731.html